Skip to main content

Breast Cancer Screening

Breast cancer is the most common malignancy in women worldwide, and screening mammography is the cornerstone of early detection — reducing breast cancer mortality by identifying invasive cancers before clinical presentation.[1] Screening is a risk-stratified process that begins with formal risk assessment (ideally by age 25) and tailors modality, frequency, and age of initiation to whether the individual is at average risk or elevated risk.[2] Urogynecologists and pelvic reconstructive surgeons encounter these patients routinely during preoperative assessment and long-term follow-up, particularly women on hormonal therapies, those with prior pelvic irradiation, and BRCA carriers being counseled about opportunistic risk-reducing surgery.

Average-risk screening​

There is broad consensus that screening mammography reduces breast cancer mortality, but major guidelines differ on when to start, how often to screen, and when to stop. Digital breast tomosynthesis (DBT) is preferred when available, as it decreases callback rates and improves cancer detection compared with standard 2D mammography alone.[2]

GuidelineStart ageFrequencyStop / Upper limit
USPSTF (2024)[1]40BiennialAge 74; insufficient evidence ≥75
NCCN (2026)[2]40AnnualNo upper limit; consider discontinuation when life expectancy ≤10 years
ACS[3]45 (option to start at 40)Annual 45–54; biennial or continued annual ≥55Continue with good health and ≥10-year life expectancy
ACR[4]40AnnualContinue beyond 74 unless severe comorbidity limits life expectancy
ACP (2026)[5]50 (shared decision-making 40–49)BiennialAge 74; discuss stopping at ≥75 or limited life expectancy

Key guideline positions:

  • USPSTF (2024): Recommends biennial screening mammography for ages 40–74 (B recommendation). This was a notable update from 2016, which had individualized the decision for ages 40–49. Evidence was deemed insufficient for screening beyond age 75 and for supplemental screening in dense breasts.[1]
  • NCCN (2026): Recommends annual mammography with tomosynthesis starting at age 40 (Category 1). Clinical encounters every 1–3 years for ages 25–39 and annually from age 40. No established upper age limit — consider discontinuation when life expectancy is ≤10 years.[2]
  • ACS: Annual mammography for ages 45–54, with the option to begin at 40; biennial screening or continued annual screening from age 55, while in good health with a life expectancy of at least ten years.[3]
  • ACR: Annual mammography starting at age 40, continuing beyond age 74 unless severe comorbidity limits life expectancy; no fixed 5–7-year threshold is given in the cited ACR/SBI statement.[15][4]
  • ACP (2026): Biennial mammography for ages 50–74; discuss benefits and harms at ages 40–49, and discuss discontinuing screening at age 75 or older or with limited life expectancy. Supports DBT for dense breasts but recommends against supplemental MRI or ultrasound in average-risk dense-breast patients.[5]

Increased-risk categories and screening​

Risk assessment should be performed by age 25 and periodically reassessed.[2] NCCN defines several increased-risk categories with distinct screening protocols.[2][6]

Residual lifetime risk ≥20% (by comprehensive family-history models)​

Annual mammography with tomosynthesis plus annual breast MRI with contrast, beginning no later than age 40. Mammography should not begin before age 30; MRI should not begin before age 25. Alternatively, begin 10 years before the youngest affected family member's diagnosis.[2]

Known genetic predisposition (e.g., BRCA1/2)​

  • Ages 25–29: Annual breast MRI with contrast (mammography only if MRI unavailable).
  • Ages 30–75: Annual mammography with tomosynthesis plus annual breast MRI with contrast.
  • Risk-reducing mastectomy counseling is indicated.[6]

Prior chest radiation (ages 10–30)​

Use a dedicated high-risk pathway that accounts for treatment age and elapsed time. The ACR 2025 criteria specify mammography eight years after young-age thoracic/upper-abdominal radiation, not before age 25, with supplemental MRI according to the risk-based schedule. Do not combine age cutoffs from different organizations into a single rule.[16][2]

5-year Gail risk ≥1.7%, atypical ductal hyperplasia (ADH), or lobular neoplasia (LCIS / ALH)​

Annual mammography with tomosynthesis; consider annual MRI. Clinical encounters every 6–12 months.[2]

Dense breast tissue (heterogeneously or extremely dense)​

Recommendations differ. ACR supports supplemental contrast MRI for appropriate dense-breast risk categories, whereas USPSTF finds evidence insufficient to determine the overall benefit–harm balance and ACP 2026 recommends against supplemental MRI/ultrasound for average-risk dense breasts. Discuss the patient's total risk, local guideline and additional recalls/biopsies; density alone is not a universally agreed MRI mandate.[1][5][16]

The DENSE trial showed fewer interval cancers after invitation to MRI among women aged 50–75 with extremely dense breasts and a normal mammogram. The endpoint was interval cancer, not a demonstrated mortality benefit. The reported NCCN 2026 category-specific pathway should be checked directly in the current guideline when applying it.[2][7][17]

Supplemental screening modalities​

When mammography alone is insufficient — particularly in dense breasts or high-risk patients — several supplemental modalities are available.[2][7][8]

ModalityIncremental CDR per 1,000Notes
Breast MRI with contrast~13–23 additional cancersHighest CDR of all supplemental modalities; ~50% reduction in interval cancers in DENSE trial; increases false positives and biopsy rate[7][8][9][10]
Abbreviated breast MRIHigher than DBT or ultrasoundSimilar sensitivity to full-protocol MRI; shorter scan times[2][11]
Contrast-enhanced mammography (CEM)Population-dependentAn option in selected patients; do not assume equivalent CDR/recall to MRI across studies; iodinated contrast and radiation considerations[2][7]
Molecular breast imaging (MBI)Population-dependentSelected use when other modalities are unsuitable; MRI equivalence is not established; systemic radiation exposure matters[2]
Whole-breast ultrasound~3 additional cancersSignificantly lower CDR than MRI (~4× lower); increases false positives[2][8]

A modeling study demonstrated that estimated benefits and harms of density-targeted MRI strategies. Model-predicted mortality benefits are not observed trial mortality results, and the preferred strategy depends on assumptions and the weight assigned to false positives.[9]

Risk assessment tools​

Formal risk assessment should be performed by age 25 and updated periodically. NCCN recognizes several validated risk models, each with distinct inputs and use cases.[2][12]

ModelKey inputsBest use case
Tyrer-Cuzick (IBIS)Personal / family history, BRCA probability, mammographic density, hormonal factorsIncludes extended pedigree and reproductive/density factors; no universally best model
BCSCAge, race/ethnicity, family history (1st-degree), prior biopsy, breast densityHighest AUC in the density-available subgroup of the cited cohort[13]
Gail (BCRAT)Age, family history (1st-degree only), prior biopsy, ethnicityWidely used; lower discrimination; drives 5-year risk ≥1.7% threshold
BOADICEAPersonal / family history, germline mutation results, tumor pathologyIncludes detailed pedigree and genetic risk; use a version validated for the clinical population

In the cited 35,921-person mammography cohort, the tested models showed moderate discrimination (AUC about 0.61–0.64); this is not universal validation of every model or population. The BCSC model had the highest AUC among women with available breast density information.[13]

Emerging evidence: risk-based screening​

The WISDOM trial randomized 28,372 participants with median 5.1-year follow-up. Risk-based screening met noninferiority for the rate of stage ≥IIB cancers (difference −18.0 per 100,000 person-years; 95% CI −40.2 to 4.1), but did not reduce the co-primary biopsy outcome (difference 98.7 per 100,000 person-years; 95% CI −17.9 to 215.3).[14] Risk-based screening integrated:

  • Genetic testing (9 susceptibility genes plus polygenic risk score)
  • BCSC risk model
  • Four screening tiers: deferred screening (low risk) to alternating mammography / MRI every 6 months (highest risk)

Among 18,031 participants who declined randomization and entered the observational cohort, 89% chose risk-based screening. This self-selected preference is not a population-wide acceptability estimate.[14]

Special populations​

  • Age ≥75: Evidence is insufficient to assess benefits and harms of continued screening (USPSTF I statement). NCCN recommends weighing comorbidities and life expectancy, using ≤10 years as a threshold for discontinuation.[1][2]
  • Prior breast cancer: Surveillance recommendations are covered in the NCCN Breast Cancer treatment guidelines, not the screening guidelines.[2]
  • BRCA carriers (male): Clinical breast exam annually starting at age 35; consider annual mammography starting at age 50 (or 10 years before the earliest known male breast cancer in the family), particularly for BRCA2 carriers.[6]
  • Transgender individuals: NCCN endorses ACR Appropriateness Criteria for screening guidance in transgender patients.[2]
  • Racial disparities: Non-Hispanic Black women have 40% higher breast cancer mortality than White women despite lower incidence. Timely diagnostic follow-up after abnormal screening results is critical, as disparities have been documented in time to diagnostic imaging and biopsy.[1][2][10]

See Also​

References​

1. Nicholson WK, Silverstein M, Wong JB, et al. "Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement." JAMA. 2024;331(22):1918–1930. doi:10.1001/jama.2024.5534

2. National Comprehensive Cancer Network. Breast Cancer Screening and Diagnosis. Version 1.2026. Updated 2026-03-05. https://www.nccn.org

3. American Cancer Society. Breast Cancer Screening Guidelines. Official recommendations

4. Khan M, Chollet A. "Breast Cancer Screening: Common Questions and Answers." Am Fam Physician. 2021;103(1):33–41.

5. Qaseem A, Harrod CS, Balk EM, et al. "Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement From the American College of Physicians (Version 2)." Ann Intern Med. 2026. doi:10.7326/ANNALS-25-05116

6. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Updated 2026-02-19. https://www.nccn.org

7. Holt DB. "Breast Density Masking and the Need for Precision Screening." JAMA. 2026. doi:10.1001/jama.2026.2443

8. Hussein H, Abbas E, Keshavarzi S, et al. "Supplemental Breast Cancer Screening in Women With Dense Breasts and Negative Mammography: A Systematic Review and Meta-Analysis." Radiology. 2023;306(3):e221785. doi:10.1148/radiol.221785

9. Stout NK, Miglioretti DL, Su YR, et al. "Breast Cancer Screening Using Mammography, Digital Breast Tomosynthesis, and Magnetic Resonance Imaging by Breast Density." JAMA Intern Med. 2024;184(10):1222–1231. doi:10.1001/jamainternmed.2024.4224

10. Henderson JT, Webber EM, Weyrich MS, Miller M, Melnikow J. "Screening for Breast Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force." JAMA. 2024;331(22):1931–1946. doi:10.1001/jama.2023.25844

11. Comstock CE, Gatsonis C, Newstead GM, et al. "Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening." JAMA. 2020;323(8):746–756. doi:10.1001/jama.2020.0572

12. National Comprehensive Cancer Network. Breast Cancer Risk Reduction. Updated 2025-08-29. https://www.nccn.org

13. McCarthy AM, Guan Z, Welch M, et al. "Performance of Breast Cancer Risk-Assessment Models in a Large Mammography Cohort." J Natl Cancer Inst. 2020;112(5):489–497. doi:10.1093/jnci/djz177

14. Esserman LJ, Fiscalini AS, Naeim A, et al. "Risk-Based vs Annual Breast Cancer Screening." JAMA. 2025. doi:10.1001/jama.2025.24784

15. ACR/SBI. Statement on New USPSTF Breast Cancer Screening Recommendations. 2023. Official statement.

16. ACR. Appropriateness Criteria: Female Breast Cancer Screening (2025) and Supplemental Breast Cancer Screening Based on Breast Density. Screening criteria; density-specific criteria.

17. Bakker MF, et al. Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. N Engl J Med. 2019. doi:10.1056/NEJMoa1903986.